abstract |
The invention provides methods useful in reducing intestinal fat absorption in an animal, preferably a mammal including a human subject or a companion animal, which methods comprise administering to an animal in need of such reduction, an amount of an apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (MTP) inhibitor, preferably in combination with an anti-obesity agent. The invention further provides pharmaceutical compositions comprising amounts of an apo B secretion/MTP inhibitor and an anti-obesity agent, and to methods of using such compositions in reducing intestinal fat absorption in an animal, preferably a mammal including a human subject or a companion animal, in need of such reduction. The invention further provides a kit comprising an amount of an apolipoprotein B secretion/microsomal triglyceride transfer protein inhibitor and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form; an amount of an anti-obesity agent and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and a container. |